Renaxen 5 Tablets — Axitinib 5 mg (60 Tabs) Everest
Renaxen 5 mg (Axitinib) is a potent and selective tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR-1, -2, and -3). It serves as a cost-effective generic equivalent to Inlyta. By inhibiting these receptors, Axitinib blocks angiogenesis (the formation of new blood vessels), effectively starving the tumor of nutrients and oxygen.
Manufacturer: Everest Pharmaceuticals (Bangladesh). The 5 mg strength represents the standard starting dose for the treatment of advanced renal cell carcinoma.
Key Features:
- ✅ Anti-Angiogenic Mechanism: Directly halts the blood supply to the tumor, inhibiting its growth.
- ✅ Advanced RCC Standard: Proven efficacy in treating kidney cancer after failure of prior systemic treatments.
- ✅ Monthly Supply: The box is designed to cover exactly one month of treatment at the standard dosage.
Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 25.03.2026
What Customers Say
No reviews yet
Your review can be the first!